Table 1.
Characteristics included for the study of ROR1.
| First Author (Year) [Ref] |
Country | Cancer Type | No. | Detection Method | Agent Used | Cutoff Used | HR for PFS (95% CI) |
HR for OS (95% CI) |
|---|---|---|---|---|---|---|---|---|
| S. Zhang (2012) [16] |
China | Breast cancer | 295 | IHC | Alexa-647-conjugated monoclonal Ab (mAb; 4A5) | Intensity score > 50% | - | 2.30 (1.32–4.01) p = 0.003 |
| H. Zhang (2014) [30] |
China | Ovarian cancer | 100 | IHC | Rabbit polyclonal Ab (1:200, Abcam) | Staining score * ≥ 2 | 2.90 (1.64–5.13) p = 0.01 |
3.54 (1.99–6.29) p = 0.01 |
| S. Zhang (2014) [22] |
U.S.A. | Ovarian cancer | 285 | RT-PCR | N/A | Upper third expression of ROR1 mRNA | 2.0 (1.4–3.0) p = 0.0003 |
1.72 (1.22–2.42) p < 0.05 |
| H. Chang (2015) [31] |
Republic of Korea | Gastric cancer | 424 | IHC | Rabbit polyclonal antibody (1:25; Abcam) | Staining > 50% | - | 0.8 (0.53–1.21) p = 0.189 |
| Chien (2016) [21] |
China | Triple negative breast cancer | 210 | IHC | Rabbit polyclonal antibody (1:100 dilution; proteintech) | Staining score * ≥ 2 | 3.06 (1.36–6.86) p = 0.007 |
2.17 (1.07–4.39) p = 0.031 |
| Cui (2016) [32] |
U.S.A. | CLL | 1568 | IHC | Alexa-647-conjugated monoclonal Ab (mAb; 4A5) | ΔMFI (mean fluorescence intensity) > 32 | 1.69 (1.45–1.98) p < 0.0001 |
2.07 (1.48–2.90) p < 0.0001 |
| Zheng (2016) [33] |
China | Lung cancer | 161 | IHC | Anti-ROR1 (Abcam 135669, 1:20) | Staining score * > 2 | - | 4.11 (2.51–6.38) p < 0.001 |
| Zhou (2017) [35] |
China | Colorectal | 186 | IHC | Polyclonal rabbit Ab (1:20, Abcam) | Staining score * > 2 | - | 2.08 (1.31–3.29) p = 0.002 |
| Li (2017) [34] |
U.S.A. | Triple negative breast cancer | 150 | IHC | N/A | N/A | - | 1.357 (1.024–1.798) p = 0.0336 |
| Henry (2018) [36] |
Australia | Endometrial cancer | 87 | IHC | Anti-ROR1 (Abcam ab135669) | Intensity score = 3 | - | 3.74 (1.54–9.07) p = 0.004 |
| Mao (2019) [37] |
China | DLBCL | 150 | IHC | Primary polyclonal rabbit anti-ROR1 antibody (ab135669, 1:300, Abcam, Cambridge, MA) | Staining score * ≥ 4 | - | 1.67 (0.831–3.370), p = 0.149 |
| Liu (2020) [39] |
Australia | Endometrial cancer | 330 | IHC | Anti-ROR1 (1:50, #564464, BD Bioscience) | Intensity score = 3 | 2.45 (1.21–4.97) p = 0.01 |
2.48 (0.99–6.18) p = 0.05 |
| Giovanna (2020) [40] |
Switzerland | Lung adenocarcinoma | 56 | qRT-PCR | >median of expression | - | 0.769 (0.364–1.62) p = 0.4915 |
|
| Ghaderi (2020) [38] |
Sweden | DLBCL | 33 | IHC | Polyclonal antibody against ROR1 (Proteintech, Manchester, United Kingdom) | >10% (level of unequivocal cytoplasmic and/or membranous staining in the neoplastic B cells) |
- | 2.33 (1.04–5.20) p = 0.039 |
* Staining score = product of staining intensity (0–3) and percentage of ROR1 positive (1–4). ROR1, receptor tyrosine kinase-like orphan receptor 1; HR, hazard ratio; IHC, immunohistochemistry; RT-PCR, reverse transcription-polymerase chain reaction; PFS, progression-free survival; OS, overall survival; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B cell lymphoma.